BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32008868)

  • 1. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
    Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
    Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma.
    Comin CE; Novelli L; Cavazza A; Rotellini M; Cianchi F; Messerini L
    Tumori; 2014; 100(5):559-67. PubMed ID: 25343553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
    Mawas AS; Amatya VJ; Kushitani K; Kai Y; Miyata Y; Okada M; Takeshima Y
    Sci Rep; 2018 Jan; 8(1):134. PubMed ID: 29317712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.
    Miettinen M; Sarlomo-Rikala M
    Am J Surg Pathol; 2003 Feb; 27(2):150-8. PubMed ID: 12548160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
    Amatya VJ; Kushitani K; Kai Y; Suzuki R; Miyata Y; Okada M; Takeshima Y
    Mod Pathol; 2018 May; 31(5):809-815. PubMed ID: 29327712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
    Pan CC; Chen PC; Chou TY; Chiang H
    Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.
    Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
    Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of CD90 in the Differential Diagnosis of Pleural Malignant Mesothelioma, Pulmonary Carcinoma and Comparison with Calretının.
    Sahin N; Akatli AN; Celik MR; Ulutas H; Samdanci ET; Colak C
    Pathol Oncol Res; 2017 Jul; 23(3):487-491. PubMed ID: 27761727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma.
    Hiratsuka T; Yamamoto T; Yoshizawa A; Toyokuni S; Tsuruyama T
    Sci Rep; 2022 Nov; 12(1):18519. PubMed ID: 36323745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
    Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
    Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
    Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
    Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
    Ordóñez NG; Sahin AA
    Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma.
    Nakashima Y; Inamura K; Ninomiya H; Okumura S; Mun M; Kirimura S; Kobayashi M; Okubo K; Ishikawa Y
    Lung Cancer; 2020 Oct; 148():20-27. PubMed ID: 32777673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
    Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
    Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
    Manur R; Lamzabi I
    Appl Immunohistochem Mol Morphol; 2019; 27(10):e93-e96. PubMed ID: 28248731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.
    Nakagiri T; Amatya VJ; Kushitani K; Kambara T; Aoe K; Endo I; Miyata Y; Okada M; Takeshima Y
    Am J Surg Pathol; 2024 Feb; 48(2):140-149. PubMed ID: 37899530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
    Kai Y; Amatya VJ; Kushitani K; Kambara T; Suzuki R; Tsutani Y; Miyata Y; Okada M; Takeshima Y
    Histopathology; 2019 Mar; 74(4):545-554. PubMed ID: 30329165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
    Le Stang N; Burke L; Blaizot G; Gibbs AR; Lebailly P; Clin B; Girard N; Galateau-Sallé F;
    Arch Pathol Lab Med; 2020 Apr; 144(4):446-456. PubMed ID: 31389715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
    Lucas DR; Pass HI; Madan SK; Adsay NV; Wali A; Tabaczka P; Lonardo F
    Histopathology; 2003 Mar; 42(3):270-9. PubMed ID: 12605647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.